Recent News

• 04.15.2025 - Lisata Therapeutics Announces Research License with Catalent
• 03.06.2025 - Lisata Therapeutics to Present at the Investival Showcase USA
• 03.05.2025 - Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development
• 02.27.2025 - Full Year 2024 Financial Results and Business Update Conference Call
• 02.27.2025 - Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
• 02.20.2025 - Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025
• 02.10.2025 - 2025 BIO CEO & Investor Conference
• 02.05.2025 - Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
• 01.23.2025 - Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
• 01.22.2025 - 2025 Sequire Investor Summit

Recent Filings

• 02.27.2025 - 8-K Current report
• 02.27.2025 - EX-99.1 EX-99.1
• 02.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.05.2025 - 3 Initial statement of beneficial ownership of securities
• 01.23.2025 - 8-K Current report
• 01.23.2025 - EX-99.1 EX-99.1